



<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use separate sheets if necessary)		ATTY DOCKET NO. 11183-010-999 (505421-999009)	APPLICATION NO 10/643,857
		APPLICANT Scott Koenig and Maria Concetta Veri	
		FILING DATE August 14, 2003	GROUP 1641

**U.S. PATENT DOCUMENTS**

MATTER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
C.C.	A01	4,179,337	12/18/79	Davis et al.			
	A02	5,711,944	01/27/98	Gilbert et al.			
	A03	5,888,533	03/30/99	Dunn			
	A04	5,648,260	07/15/99	Winter et al.			
	A05	5,945,115	08/31/99	Dunn et al.			
	A06	6,019,968	02/01/00	Platz et al.			
	A07	6,132,764	10/17/00	Li et al.			
	A08	6,194,551	02/27/01	Idusogie et al.			
	A09	6,218,149	04/17/01	Morrison et al.			
	A10	2001/0036459	11/01/01	Ravetch			
	A11	6,339,069	01/15/02	Meers et al.			
	A12	2002/0028486	03/07/02	Morrison et al.			
	A13	6,420,149	07/16/02	Fukuda et al.			
	A14	6,472,511	10/29/02	Leung et al.			
	A15	6,528,624	03/04/03	Idusogie et al.			
C.C.	A16	2003/0115614	06/19/03	Kanda et al.			

## FOREIGN PATENT DOCUMENTS

MATTER		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
C.C.	B01	WO 94/18330	08/18/94	PCT			
	B02	EP 0 359 096	11/05/97	EPC			
	B03	WO 00/42072	07/20/00	PCT			
	B04	EP 0 343 950 B1	10/18/00	EPC			
C.C.	B05	WO 03/035835	05/01/03	PCT			

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C.C.	C01	Abra et al. The next generation of liposome delivery systems: recent experience with tumor-targeted, sterically-stabilized immunoliposomes and active-loading gradients. <i>J Liposome Res.</i> 2002 Feb-May;12(1-2):1-3
	C02	Bendas G. Immunoliposomes: a promising approach to targeting cancer therapy. <i>BioDrugs.</i> 2001;15(4):215-24.
	C03	Billadeau et al., ITAMs versus ITIMs: striking a balance during cell regulation, <i>J Clin Invest.</i> 2002 Jan;109(2):161-8.
	C04	Bolland and Ravetch. Inhibitory pathways triggered by ITIM-containing receptors. <i>Adv Immunol.</i> 1999;72:149-177.
C.C.	C05	Bolland et al. Genetic modifiers of systemic lupus erythematosus in FcgammaRIIB(-/-) mice. <i>J Exp Med.</i> 2002 May 6;195(9):1167-74
	C06	Boruchov et al., Expression and modulation of the inhibitory Fcgamma receptor, FcgammaRIIB (CD32b), on human dendritic cells (DCs). Laboratory of Cellular Immunobiology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, NY, NY 10021

AE  
7-30-08



Express Mail No. EV 452 775 784 US  
Sheet 1 of 1

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY DOCKET NO.  
11183-010-999

APPLICATION NO  
10/643,857

APPLICANT  
Koenig et al.

FILING DATE  
August 14, 2005

GROUP  
~~1641~~ 1644

**U.S. PATENT DOCUMENTS**

MATTER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
C.C.	A17	5,837,243	1998	11/17/1997	Deo et al.		

**FOREIGN PATENT DOCUMENTS**

MATTER		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
C.C.	B06	WO 99/58572 A1	11/18/1999	PCT				
C.C.	B07	WO 01/79299 A1	10/25/2001	PCT				
C.C.	B08	WO 03/066095 A2	08/14/2003	PCT				
C.C.	B09	EP 1 006 183 A1	06/07/2000	EP				

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

C.C.	C71	Ding et al., Inhibition of the function of the FcγRIIB by a monoclonal antibody to thymic shared antigen-1, a Ly-6 family antigen. Immunology. 2001 Sep;104(1):28-36

EXAMINER

*h g*

DATE CONSIDERED

3/14/07

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.